Skip to main
PRTA
PRTA logo

Prothena (PRTA) Stock Forecast & Price Target

Prothena (PRTA) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 11%
Sell 11%
Strong Sell 0%

Bulls say

Prothena Corp PLC has demonstrated favorable results in its clinical trials, particularly in reducing amyloid levels in patients, which is a significant milestone for its investigational therapies targeting neurodegenerative and amyloid diseases. The company has guided potential earnings of up to $105 million in aggregate milestones by 2026 from collaborations with Novo Nordisk and Bristol-Myers Squibb, highlighting the financial upside tied to its advancing pipeline. Additionally, the favorable safety profile of PRX012, despite elevated ARIA incidence, points to the potential for further development and market acceptance of Prothena's therapies.

Bears say

Prothena Corp's stock faces a negative outlook as the company is expected to continue incurring net losses until it achieves product approval and commercialization, potentially extending through the early launch phase. The need for additional capital to fund the development of its drug candidates raises concerns over potential dilution for shareholders, as the timeline and success of these candidates remain uncertain. Furthermore, evolving regulatory dynamics pose additional risks, potentially complicating pathways to approval and introducing further commercial obstacles.

Prothena (PRTA) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prothena (PRTA) Forecast

Analysts have given Prothena (PRTA) a Buy based on their latest research and market trends.

According to 9 analysts, Prothena (PRTA) has a Buy consensus rating as of Dec 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prothena (PRTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.